220 related articles for article (PubMed ID: 19188835)
1. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits.
D'Annunzio V; Donato M; Erni L; Miksztowicz V; Buchholz B; Carrión CL; Schreier L; Wikinski R; Gelpi RJ; Berg G; Basso N
J Cardiovasc Pharmacol; 2009 Feb; 53(2):137-44. PubMed ID: 19188835
[TBL] [Abstract][Full Text] [Related]
2. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
Di Napoli P; Taccardi AA; Grilli A; De Lutiis MA; Barsotti A; Felaco M; De Caterina R
Cardiovasc Res; 2005 Jun; 66(3):462-71. PubMed ID: 15914111
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Bulhak A; Roy J; Hedin U; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition.
Giricz Z; Lalu MM; Csonka C; Bencsik P; Schulz R; Ferdinandy P
J Pharmacol Exp Ther; 2006 Jan; 316(1):154-61. PubMed ID: 16166272
[TBL] [Abstract][Full Text] [Related]
6. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
Bulhak AA; Gourine AV; Gonon AT; Sjöquist PO; Valen G; Pernow J
Acta Physiol Scand; 2005 Feb; 183(2):151-9. PubMed ID: 15676056
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction.
Dourado PM; Tsutsui JM; Landim MB; Casella Filho A; Galvao TF; Aiello VD; Mathias W; da Luz PL; Chagas AC
Braz J Med Biol Res; 2011 May; 44(5):469-76. PubMed ID: 21445530
[TBL] [Abstract][Full Text] [Related]
8. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
Sicard P; Lauzier B; Oudot A; Busseuil D; Collin B; Duvillard L; Moreau D; Vergely C; Rochette L
Arch Mal Coeur Vaiss; 2005; 98(7-8):804-8. PubMed ID: 16220751
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism.
Liuni A; Luca MC; Gori T; Parker JD
J Am Coll Cardiol; 2010 Mar; 55(10):1002-6. PubMed ID: 20202516
[TBL] [Abstract][Full Text] [Related]
10. Role of matrix metalloproteinase-2 in the cardioprotective effect of ischaemic postconditioning.
Donato M; D'Annunzio V; Buchholz B; Miksztowicz V; Carrión CL; Valdez LB; Zaobornyj T; Schreier L; Wikinski R; Boveris A; Berg G; Gelpi RJ
Exp Physiol; 2010 Feb; 95(2):274-81. PubMed ID: 19880538
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury.
Ke D; Fang J; Fan L; Chen Z; Chen L
Coron Artery Dis; 2013 Jun; 24(4):334-41. PubMed ID: 23531479
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
Weinberg EO; Scherrer-Crosbie M; Picard MH; Nasseri BA; MacGillivray C; Gannon J; Lian Q; Bloch KD; Lee RT
Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1802-9. PubMed ID: 15563531
[TBL] [Abstract][Full Text] [Related]
13. [Rosuvastatin enhances the protective effects of ischemic postconditioning on myocardial ischaemia-reperfusion injury in type 2 diabetic rat].
CAI W; FANG J; CHEN ZY; LIN YL; WU LM; CHEN LL
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Sep; 38(9):814-8. PubMed ID: 21092651
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
[TBL] [Abstract][Full Text] [Related]
15. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
16. [Precondition with doxycycline administration abates ischemia/reperfusion injury and reduces the expression of matrix metalloproteinase-1/9 in myocardium in rat in vivo].
Wu LM; Fan L; Chen LL
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Nov; 19(11):679-82. PubMed ID: 17996137
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion.
Fert-Bober J; Leon H; Sawicka J; Basran RS; Devon RM; Schulz R; Sawicki G
Basic Res Cardiol; 2008 Sep; 103(5):431-43. PubMed ID: 18512095
[TBL] [Abstract][Full Text] [Related]
18. Ischemic postconditioning reduces infarct size by activation of A1 receptors and K+(ATP) channels in both normal and hypercholesterolemic rabbits.
Donato M; D'Annunzio V; Berg G; Gonzalez G; Schreier L; Morales C; Wikinski RL; Gelpi RJ
J Cardiovasc Pharmacol; 2007 May; 49(5):287-92. PubMed ID: 17513947
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats.
Ikeda Y; Young LH; Lefer AM
J Cardiovasc Pharmacol; 2003 Apr; 41(4):649-56. PubMed ID: 12658068
[TBL] [Abstract][Full Text] [Related]
20. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.
Vilahur G; Casaní L; Peña E; Duran X; Juan-Babot O; Badimon L
Atherosclerosis; 2009 Sep; 206(1):95-101. PubMed ID: 19419716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
